Priya B. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Priya B. Patel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ameera B. A. Jailani
University of Sheffield
1 shared publication - Amy Kwan
Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
1 shared publication - Caroline Wilson
Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, UK
1 shared publication - Claire Elizabeth Lewis
Division of Clinical Medicine, School of Medicine & Population Health, Faculty of Health, Sheffield, United Kingdom
1 shared publication - Emer Atkinson
Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, SHEFFIELD S10 2RX, UK
1 shared publication - Faith Howard
School of Medicine and Population Health, The University of Sheffield, Barber House, Sheffield S10 2HQ, UK
1 shared publication
Latest Publications
- Open Access
- 21 October 2022
- Published by MDPI AG in Future Pharmacology
- Vol. 2 (4) , 444-459
Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intravenous administration of a virus has the potential to result in neutralization and sequestration of the virus which may reduce efficacy. Here, we show that the oncolytic virus HSV1716 can be administered within a cellular carrier (macrophages). PyMT and 4T1 murine mammary cancer cell lines were implanted into immuno-competent murine models (orthotopic primary, early metastatic and brain metastasis models). HSV1716 or macrophages armed with HSV1716 (M-HSV1716) were administered intravenously, and tumour size was quantified using caliper measurement or bioluminescence imaging. Administration of M-HSV1716 led to tumour shrinkage and increased the survival of animals. Furthermore, these results were achieved with a 100-fold lower viral load, which has the potential for decreased toxicity. Our results demonstrate that M-HSV1716 is associated with activity against murine mammary cancers and provides an alternative platform for the systemic delivery of OV.
- 21 October 2022
- Published by MDPI AG in Future Pharmacology
- Vol. 2 (4) , 444-459
Open AccessMacrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective treatment for mammary cancer. However, intravenous administration of a virus has the potential to result in neutralization and sequestration of the virus which may reduce efficacy. Here, we show that the oncolytic virus HSV1716 can be administered within a cellular carrier (macrophages). PyMT and 4T1 murine mammary cancer cell lines were implanted into immuno-competent murine models (orthotopic primary, early metastatic and brain metastasis models). HSV1716 or macrophages armed with HSV1716 (M-HSV1716) were administered intravenously, and tumour size was quantified using caliper measurement or bioluminescence imaging. Administration of M-HSV1716 led to tumour shrinkage and increased the survival of animals. Furthermore, these results were achieved with a 100-fold lower viral load, which has the potential for decreased toxicity. Our results demonstrate that M-HSV1716 is associated with activity against murine mammary cancers and provides an alternative platform for the systemic delivery of OV.